Doppl
Doppl SA is a Lausanne-based organoid technology company founded in 2022 that engineers standardized 3D cell-based disease models and runs a crowd-sourced citizen-donor Bio-base, serving pharmaceutical, biotech, and academic clients in preclinical drug development and personalized medicine research.
- Company typePrivate
- Founded2022
- HeadquartersLausanne, Switzerland
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Doppl does
Doppl SA is a Lausanne, Switzerland-based organoid technology company founded in 2022 that engineers standardized 3D cell-based organoid models for disease modeling and personalized medicine. At the core of its offering is the Bio-base, a crowd-sourced database of biological samples contributed by citizen donors who retain control over their data, paired with the Gri3D organoid platform technology (a registered trademark) and the Bionoid test applied in cystic fibrosis and other rare disease research. The company ran three primary service lines: Compound Profiling (toxicity screening using human healthy gastro-intestinal organoids), Epithelial Fluid Transport screening, and Model Development (customized organoid lines for client-specified tissues or diseases), with applications spanning oncology, immuno-oncology, inflammatory diseases, ADME-Tox, and rare disease therapeutics.
Doppl firmographics
Firmographics- Name
- Doppl
- Legal name
- Doppl SA
- Website
- https://doppl.ch
- Company type
- Private
- Founded year
- 2022
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- Doppl SA is a Lausanne-based organoid technology company founded in 2022 that engineers standardized 3D cell-based disease models and runs a crowd-sourced citizen-donor Bio-base, serving pharmaceutical, biotech, and academic clients in preclinical drug development and personalized medicine research.
- Ownership category
- akta.pro rank
Doppl industry classification
Industry- Product category
- Preclinical Drug Development Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)
- akta.pro secondary industries
- Organoids & Organ-on-Chip (regenerative models) (HLAAAGAD), DMPK / ADME & Bioanalysis (HLAGAFAC)
Keywords
Where Doppl is headquartered
LocationHeadquarters
- HQ city
- Lausanne
- HQ country
- Switzerland
- HQ region
- Europe
Offices1 record
Markets served
Doppl business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- Organoid Model Development Services: Custom organoid lines developed to accurately model specific tissues or diseases of interest for pharmaceutical clients. Revenue generated through project-based service contracts with biotech and pharma companies.
- Compound Profiling Services: Toxicity screening services using established models of human healthy gastro-intestinal organoids for preclinical drug development.
- Epithelial Fluid Transport Screening: Screening services for epithelial fluid transport using human healthy gastro-intestinal organoid models.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | B2B enterprise pricing for organoid services |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Doppl product offering
Product offeringCore offering
Doppl engineers industry-standard human organoids and organs-on-chip models for disease modeling and personalized medicine, engaging in partnered preclinical drug development projects for pharmaceutical and biotech clients. The company delivers three core services—compound toxicity profiling, epithelial fluid transport screening, and customized organoid line development—backed by the Bio-base crowd-sourced database of biological samples contributed by citizen donors who retain control over their data.
Product overview
Doppl SA is a company specializing in engineering industry-standard organoids for disease modeling and personalized medicine. The company operates the Bio-base, a crowd-sourced database of biological samples that enables research and drug development. Doppl offers three core services: Compound Profiling (toxicity screening), Epithelial Fluid Transport screening, and Model Development (customized organoid lines). The company also developed the Bionoid Test for precision medicine applications. The portfolio spans applications in oncology, inflammatory diseases, rare diseases (including cystic fibrosis), immuno-oncology, and ADME-Tox testing.
Differentiator
Problem solved
Functional benefit
Products and services
- Compound Profiling Toxicity screening service using an established model of human healthy gastro-intestinal organoids to assess compound safety profiles for pharmaceutical and biotech preclinical drug development clients.
- Epithelial Fluid Transport Screening service for epithelial fluid transport using established models of human healthy gastro-intestinal organoids, supporting preclinical drug development and translational research for pharmaceutical clients.
- Model Development Customized organoid line development service that accurately models specific tissues or diseases of interest, built to client specifications for preclinical research and drug development programs.
- Bio-base A global, crowd-sourced database of biological samples used to power critical research and drug development. Citizen donors contribute biological data while retaining control over their samples, supporting personalized medicine initiatives and supplying material for Doppl's organoid services.
- Bionoid Test
Quantifiable outcome
- Expanded Bionoid test validation from 1 to 11 cystic fibrosis patients
Companies that use Doppl
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles3 records
Doppl technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Doppl partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and supporting.
- EPFL (École Polytechnique Fédérale de Lausanne)coreEPFL serves as a key research and innovation partner, hosting Doppl's headquarters in the EPFL Innovation Building L. The partnership provides access to academic research capabilities and facilities.
- CHUV (Centre Hospitalier Universitaire Vaudois)coreCHUV is a university hospital partner collaborating with Doppl on clinical research and organoid applications. The partnership enables hospital-laboratory collaboration for personalized medicine research.
- TecansupportingLaboratory instrumentation partner providing automation and liquid handling solutions that integrate with Doppl's organoid production workflows.
- PromegasupportingLife sciences reagent partner providing biological assays and reagents for Doppl's screening and profiling services.
- Scientist.comsupportingOnline research services marketplace that connects pharma and biotech companies with research service providers including Doppl.
- InSphero AGcoreInSphero AG acquired DOPPL SA including the Gri3D technology in November 2025, representing a significant strategic transition where Doppl's technology became integrated into InSphero's 3D cell model offerings for pharmaceutical R&D.
Scale indicators2 records
Recent moves6 records
Expansion highlights5 records
Doppl competitors and assessment
Company assessmentMarket position
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Doppl social profiles
Digital presenceDoppl financial estimates
Financial estimateRevenue estimate
Valuation estimate
Doppl leadership team
Management profileNumber of profiles
Profiles12 records
Doppl funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Doppl M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Doppl
What does Doppl do?
Doppl engineers industry-standard human organoids and organs-on-chip models for disease modeling and personalized medicine, engaging in partnered preclinical drug development projects for pharmaceutical and biotech clients. The company delivers three core services—compound toxicity profiling, epithelial fluid transport screening, and customized organoid line development—backed by the Bio-base crowd-sourced database of biological samples contributed by citizen donors who retain control over their data.
Is Doppl a public or private company?
Doppl is a private company. It is classified as corporate owned and is currently acquired.
When was Doppl founded?
Doppl was founded in 2022. It employs 11 to 50 people.
Where is Doppl based?
Doppl is headquartered in Lausanne, Switzerland, in the Europe region.
How does Doppl make money?
Three revenue lines are on record. Organoid Model Development Services are the primary driver. The others are compound Profiling Services and epithelial Fluid Transport Screening.
Does Doppl have an API?
No public API is recorded for Doppl.
What industry is Doppl in?
Doppl's product category is Preclinical Drug Development Services. Its primary akta.pro industry code is HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems), with a secondary code of HLAAAGAD, Organoids & Organ-on-Chip (regenerative models). Its NAICS code is 541714 and its SIC code is 8731.